Business Context and Reporting Period
Kura Oncology, Inc. filed this Form 8-K on January 8, 2020, to disclose the entry into a material definitive agreement. The company is a Delaware corporation with its principal executive offices located in San Diego, California.
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, or liquidity metrics. The document focuses exclusively on a new lease agreement.
- Lease Commencement: Expected May 1, 2020.
- Lease Term: Initial term of five years and four months, with one option to extend for five additional years.
- Minimum Rent: Approximately $57,700 per month for the first year, increasing by 3.0% annually.
- Additional Costs: Company responsible for its share of operating expenses, taxes, utilities, and parking.
Material Changes
The company entered into a new Office Lease for approximately 13,420 square feet at 12730 High Bluff Drive, San Diego, California. This location will serve as the company's new principal executive offices and general office space. This represents a change in the company's physical footprint and future fixed cost structure.
Outlook, Risks, and Contingencies
The filing notes that in the event of a default on certain obligations, the Landlord has the right to terminate the lease and recover unpaid rent and expenses. The full text of the lease will be filed as an exhibit to the Annual Report on Form 10-K for the year ended December 31, 2019.
Investor Verification Checklist
- Verify the total projected cost of the lease over the initial term including the 3.0% annual escalations.
- Confirm the exact square footage and specific operating expense ratios in the full lease agreement.
- Review the upcoming Form 10-K for the complete text of the lease and any related financial impact analysis.
- Assess the impact of the new fixed rent obligation on the company's cash burn rate given its pre-revenue status.